Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
M Janusz MezynskiAngela M FarrellyMattia CremonaAoife CarrClare MorganJulie WorkmanPaul ArmstrongJennifer McAuleyStephen MaddenJoanna FayKatherine M SheehanElaine W KayCiara HolohanYasir ElaminShereen RafeePatrick G MorrisOscar BreathnachLiam GroganBryan T HennessySinead ToomeyPublished in: Journal of translational medicine (2021)
PI3K or MEK inhibition alone or in combination with anti-HER2 therapy may represent an improved treatment strategy for some patients with HER2-positive GC, and warrants further investigation in a clinical trial setting.